论文部分内容阅读
目的 :探讨后程加速超分割放射治疗肺鳞癌的临床效果。方法 :12 0例肺鳞癌随机均分为两组。常规分割放射治疗组 (CF组 ) :2 .0 Gy/次 ,1次 / d,5次 /周 ,大野照射至 DT4 0 Gy(分 2 0次 ,4周完成 )后缩野照射临床肿瘤区 ,总量达 6 5 Gy～ 70 Gy,总疗程 6 .5周～ 7.0周 ;后程加速超分割放射治疗 (L CAF)组 :前 2 / 3疗程放射治疗方法同常规放射治疗组 ,缩野后加速超分割照射 ,1.2 Gy/次 ,2次 / d,间隔 6 h;照射 10个治疗日 ,总剂量达 6 4 Gy,总疗程 6周 ,照射野设计及放射线类型两组均相同。结果 :(1)疗程 :总有效率 (CR+PR)率 L CAF组为 86 .7% ,CF组为 6 1.7% ,两组总有效率差异有显著性意义 (P<0 .0 5 )。 1年、2年生存率和局部控制率 L CAF组分别为 73.3%、6 3.3%和 6 8.3%、4 5 % ,CF组分别为 5 6 .6 %、2 6 .7%和 5 0 %、18.3%两组差异有显著性意义 (P<0 .0 5 )。 (2 )放射性气管炎 ,肺炎均无差异。 (3)放射性食管炎 :L CAF组为 78.3% ,CF组为 5 5 %。结论 :后程加速超分割放射治疗肺鳞癌 ,患者均能耐受 ,近期疗效和 1年、2年生存率及局部控制率明显优于常规放疗 ,是一种值得推广的好方法
Objective: To investigate the clinical effect of late accelerated hyperfractionation radiotherapy for squamous cell carcinoma of the lung. Methods: 120 cases of squamous cell carcinoma were randomly divided into two groups. Conventional fractionated radiotherapy group (CF group): 2.0 Gy / time, once / d, 5 times / week, field irradiation DT4 0 Gy (2 0 times, 4 weeks to complete) , With a total dose of 65 Gy to 70 Gy, with a total duration of 6.5 weeks to 7.0 weeks. Late-course accelerated hyperfractionation radiotherapy (L CAF) group: The first two-thirds of course radiotherapy was the same as that of the conventional radiotherapy group, After accelerated hyperspectral irradiation, 1.2 Gy / time, 2 times / d, interval 6 h; irradiation for 10 treatment days, the total dose of 64 Gy, the total course of 6 weeks, radiation field design and radiation type were the same in both groups. Results: (1) The course of treatment: The total effective rate (CR + PR) rate was 86.7% in CAF group and 67.7% in CF group. There was significant difference between the two groups in total effective rate (P <0.05) . The 1-year, 2-year survival rates and local control rates were 73.3%, 63.3% and 65.3%, 45% in the L CAF group and 56.6%, 26.7% and 50%, respectively in the CF group , 18.3% difference between the two groups was significant (P <0. 05). (2) Radiation tracheitis, pneumonia were no difference. (3) Radiation esophagitis: L CAF group was 78.3%, CF group was 55%. Conclusions: Late-course accelerated hyperfraction radiotherapy for squamous cell carcinoma of the lung can be tolerated. The short-term efficacy, 1 year, 2 year survival rate and local control rate are obviously superior to conventional radiotherapy. This is a good method worthy of promotion